女性肺癌和乳腺癌患者中阿瑞匹坦与奥氮平预防多日化疗所致延迟性恶心呕吐的疗效观察

发布时间：2018-08-08 20:57

【摘要】：目的评估阿瑞匹坦/奥氮平联合托烷司琼和地塞米松方案在多日顺铂化疗的女性患者中的有效性、安全性和费用效益比。方法采用随机对照研究方法,将87例女性肿瘤患者随机分为阿瑞匹坦组(44例)和奥氮平组(43例)。阿瑞匹坦组止吐方案:阿瑞匹坦、托烷司琼和地塞米松;对照组方案:奥氮平、托烷司琼和地塞米松。结果 44例阿瑞匹坦组患者中,29例患者(65.9%)延迟期呕吐达到完全缓解,43例患奥氮平组患者中,30例(69.8%)延迟期呕吐达到完全缓解,两组比较差异无统计学意义(P=0.690)。阿瑞匹坦组呃逆发生率更高(P=0.023),其余不良反应两组差异无统计学意义;而奥氮平导致的嗜睡作用更明显(P=0.006)。血液学毒性方面两组之间差异无统计学意义。每周期阿瑞匹坦组的费用明显高于奥氮平组(P0.01)。结论奥氮平联合托烷司琼和地塞米松用于女性肺癌和乳腺癌患者多日化疗所致的延迟性恶心呕吐安全性和有效性与阿瑞匹坦联合托烷司琼和地塞米松相似,但更具有费用效益比优势。
[Abstract]:Objective to evaluate the efficacy, safety and cost-effectiveness of the combination of tropisetron and dexamethasone in multiday cisplatin chemotherapy in women. Methods 87 female patients with tumor were randomly divided into two groups: Aripitan group (n = 44) and olanzapine group (n = 43). The control group: olanzapine, tropisetron and dexamethasone. Results 29 (65.9%) patients (65.9%) with delayed vomiting achieved complete remission in 44 patients (65.9%). 30 (69.8%) of 43 patients with olanzapine had complete remission of delayed vomiting. There was no significant difference between the two groups (P0. 690). The incidence of hiccup in group A was higher than that in group A (P0. 023), but there was no significant difference in other adverse reactions between the two groups, while olanzapine had a more obvious effect on lethargy (P0. 006). There was no significant difference in hematological toxicity between the two groups. The cost per cycle of Arepitan group was significantly higher than that of olanzapine group (P0.01). Conclusion the safety and efficacy of olanzapine combined with tropisetron and dexamethasone in the treatment of delayed nausea and vomiting induced by multiple days chemotherapy in female patients with lung cancer and breast cancer are similar to those of aripitan combined with tropisetron and dexamethasone. But it has the advantage of cost-benefit ratio.
【作者单位】：湖北省肿瘤医院胸部肿瘤内科;荆州市第三人民医院肿瘤科;
【分类号】：R734.2;R737.9

【相似文献】